Comparison between post op dropless treatment versus traditional with drop treatment

A prospective, randomized, comparative clinical study to compare dropless cataract surgery regime and conventional post cataract treatment regime. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084964

Enrollment

320

Registered

2025-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H258- Other age-related cataract

Interventions

Intervention1: intracameral antibiotic and Sub-Tenon s steriod injection immediate post op: Sub-Tenon s triamcinolone acetonide (12 mg/ml) and 0.1ml intracameral moxifloxacin (0.5%) (Auromox, Aurolab,

Eligibility

Inclusion criteria

Inclusion criteria: Primary cataract surgery (age-related cataract) requiring phacoemulsification. Patients with cataracts with nuclear opalescence grade 1-3, cortical cataract, posterior subcapsular cataract Preoperative best-corrected visual acuity worse than 20/40. No history of ocular trauma, glaucoma, diabetic retinopathy, or other retinal pathology.

Exclusion criteria

Exclusion criteria: History of previous eye surgery (except for uncomplicated cataract surgery in the other eye). Active ocular infection or inflammation (KNOWN CASE OF HSV OR RETROVIRAL/HEPATITIS) . Systemic conditions contraindicating steroid use (e.g., active systemic infection, poorly controlled diabetes). Complicated cataracts History of uveitis, glaucoma, HIGH myopia. Allergy to Triamcinolone Acetonide, Moxifloxacin, or any other components of the study drugs.

Design outcomes

Primary

Measure	Time frame
Best-Corrected Visual Acuity (BCVA) at postoperative day 1, 15 days, month 1, 3, and 6. Intraocular Pressure (IOP) at postoperative day 1, 15 days, month 1, 3, and 6. AC reaction (measured via anterior chamber cell count and flare according to SUN classification) - as measured on slit lamp. OCT - macula- central sub retinal thickness (Optovue RTVue100, USA) - 15 days Timepoint: postoperative days 1, 15, month 1, 3 and 6	—

Measure

Time frame

Best-Corrected Visual Acuity (BCVA) at postoperative day 1, 15 days, month 1, 3, and 6. Intraocular Pressure (IOP) at postoperative day 1, 15 days, month 1, 3, and 6. AC reaction (measured via anterior chamber cell count and flare according to SUN classification) - as measured on slit lamp. OCT - macula- central sub retinal thickness (Optovue RTVue100, USA) - 15 days Timepoint: postoperative days 1, 15, month 1, 3 and 6

—

Secondary

Measure	Time frame
Rate of Postoperative Complications (e.g., endophthalmitis, posterior capsule opacification, macular edema, elevated IOP). Patient Satisfaction (subjective questionnaire at 1 and 3 months). Steroid Use: Number of patients requiring additional steroids. Timepoint: postoperative days 1, 15, month 1, 3 and 6	—

Countries

India

Contacts

Public ContactDr. Manasaveena N T

Nethradhama Super Speciality Eye Hospital

manasa.veena2412@gmail.com9060630060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026